Skip to content
DataLookout
Menu

NCT02535312

Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin

StatusActive, Not Recruiting
PhasePhase 1/2
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

The 50 most recent of 140 versions: 14 with changes below, 36 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Minor Study completion pushed from Oct 15, 2026 to Oct 15, 2027
  2. Notable Eligibility criteria expanded, about 1 word
    • Study completion date: Oct 15, 2026 to Oct 15, 2027
    • Secondary endpoints: details revised at 1 of 2 entries
    • Site details revised at 3 of 14 sites
  3. Minor Study sites revised (14)v139
  4. Minor Study sites revised (14)v113
  5. Minor Study completion date: Oct 17, 2025 to Oct 15, 2026v112
Show 10 earlier versionsHide 10 earlier versions
  1. Minor Study completion date: Oct 17, 2024 to Oct 17, 2025v109
  2. Minor Study sites revised (14)v107
  3. Minor Study sites revised (14)v106
  4. Notable Results first posted: Apr 25, 2024
    • Primary endpoints: 2 to 3
    • Secondary endpoints: 4 to 2
    v105
  5. Minor Enrollment target: estimated 58 to confirmed 30
    • Primary completion date changed from estimate of Dec 31, 2023 to Dec 31, 2022
    • Study completion date: Dec 31, 2023 to Oct 17, 2024
    v104
  6. Notable Primary and study completion dates: Dec 31, 2022 to Dec 31, 2023
    • Start date: Aug 11, 2015 to Mar 8, 2016
    • Study sites revised (14)
    v103
  7. Minor Study sites revised (14)v98
  8. Notable Primary and study completion dates: Dec 31, 2021 to Dec 31, 2022v97
  9. Notable Primary and study completion dates: Dec 31, 2020 to Dec 31, 2021v93
  10. Minor Study completion date: Dec 31, 2020v92
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Number of Participants With at Least One Dose Limiting Toxicity (DLT) - Phase I
Timeframe: During the first cycle of treatment, up to 21 days
Maximum Tolerated Dose (MTD)
Timeframe: 21 days from start of treatment, up to 2 years
Number of Subject With Overall Response
Timeframe: Up to 8 weeks post-treatment

Secondary (2)

Progression-free Survival
Overall Survival

Arms and interventions

Arm A (methoxyamine, pemetrexed disodium, cisplatin)Experimental

Patients receive methoxyamine PO QD on days 1-4, pemetrexed disodium IV over 10 minutes, and cisplatin IV over 30-60 minutes on day 1. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients may continue methoxyamine and pemetrexed disodium beyond cycle 6 if the patient continues to benefit from treatment at the discretion of the treating physician.

Arm B (methoxyamine, pemetrexed disodium)Experimental

Patients receive methoxyamine PO QD on days 1-4 and pemetrexed disodium IV over 10 minutes on day 1. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients may continue methoxyamine and pemetrexed disodium beyond cycle 6 if the patient continues to benefit from treatment at the discretion of the treating physician.

Drugs: Cisplatin, Methoxyamine, Pemetrexed Disodium

Sites

14 sites in 1 country